ABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/drug therapy , Groin/pathology , Prednisone/administration & dosage , Pemphigoid, Bullous/pathology , Skinfold Thickness , Erythema/pathology , Epidermis/pathology , Biopsy , Achondroplasia/pathology , Papilloma/pathology , Hyperkeratosis, Epidermolytic/pathology , Parakeratosis/pathology , Fluorescent Antibody Technique, DirectABSTRACT
BACKGROUND AND OBJECTIVE: Studies on the use of systemic therapy for psoriasis in pediatric patients are scarce. The main aim of this study was to describe the systemic treatments used for moderate to severe psoriasis in pediatric clinical settings. The second aim was to describe the effectiveness and safety of these treatments. MATERIAL AND METHODS: Descriptive, cross-sectional, multicenter study of patients under 18 years of age with moderate to severe psoriasis who were being treated or had been treated with a systemic drug (conventional or biologic) or phototherapy. We recorded demographic and clinical information, treatments received, tolerance, adverse effects, and response to treatment. RESULTS: Data were collected for 40 patients (60% female; mean age, 13 years) who had received 63 treatments in total. The most common first treatment (n=40) was phototherapy (administered to 68% of patients), followed by acitretin (15%). The most common treatments overall (n=63) were phototherapy (57%) and methotrexate (16%). At week 12 (evaluation of systemic treatment and phototherapy), 66% of the patients were classified as good responders and 22% as partial responders. The respective rates for week 24 (evaluation of systemic treatment only) were 36% and 32%. The treatments were well tolerated (97%) and adverse effects were reported in just 11% of cases. There were no treatment discontinuations because of adverse effects. CONCLUSIONS: Phototherapy, followed by methotrexate, was the most common treatment for moderate to severe psoriasis in this series of patients under 18 years. The treatments showed a favorable safety profile and were associated with a good response rate of 66% at week 12 (systemic treatment and phototherapy) and 36% at week 24 (systemic treatment only).
Subject(s)
Psoriasis/therapy , Acitretin/therapeutic use , Adolescent , Child , Comorbidity , Cross-Sectional Studies , Drug Utilization , Humans , Methotrexate/therapeutic use , Phototherapy , Procedures and Techniques Utilization , Psoriasis/drug therapy , Psoriasis/epidemiology , SpainABSTRACT
ANTECEDENTES Y OBJETIVO: Los trabajos sobre el tratamiento sistémico de la psoriasis en edad pediátrica son escasos. El objetivo principal de este trabajo consistió en describir qué tratamientos sistémicos se emplean en práctica clínica en psoriasis moderada-grave en edad pediátrica. Secundariamente se describió la efectividad y perfil de seguridad de dichos tratamientos. MATERIALES Y MÉTODOS: Estudio descriptivo transversal multicéntrico, de los pacientes con psoriasis moderada-grave, que siendo menores de 18 años estuviesen recibiendo o hubieran recibido tratamiento sistémico (clásico o biológico) o fototerapia. Se recogieron datos clínico-demográficos, tipo de tratamiento recibido, y tolerancia, efectos indeseables y respuesta al mismo. RESULTADOS: Se obtuvieron datos de 40 pacientes (60% sexo femenino, edad media 13 años), que realizaron 63 ciclos de tratamiento. Teniendo en cuenta el primer tratamiento (n = 40), la fototerapia fue la opción más frecuente (68%), seguida de acitretino (15%). Considerando el total de ciclos de tratamiento (n = 63), el tratamiento más frecuentemente empleado fue la fototerapia (57%), seguida de metotrexato (16%). En la semana 12 (incluye evaluación de fototerapia), el 66% y el 22% fueron buenos respondedores o respondedores parciales, respectivamente. En la semana 24 (datos exclusivos sobre fármacos sistémicos), el 36% y el 32% continuaron con respuestas buenas y parciales. Los tratamientos fueron bien tolerados (97%) y los efectos indeseables escasos (11%), sin que en ningún caso motivasen la suspensión del fármaco. CONCLUSIONES: En la población menor de 18 años con psoriasis moderada-grave evaluada la fototerapia fue el tratamiento más utilizado, seguida de metotrexato. Los tratamientos consiguieron porcentajes de buenos respondedores del 66% en la semana 12 (incluida fototerapia), y del 36% en la semana 24 (fármacos sistémicos sin fototerapia), presentando un buen perfil de seguridad
BACKGROUND AND OBJECTIVE: Studies on the use of systemic therapy for psoriasis in pediatric patients are scarce. The main aim of this study was to describe the systemic treatments used for moderate to severe psoriasis in pediatric clinical settings. The second aim was to describe the effectiveness and safety of these treatments. MATERIAL AND METHODS: Descriptive, cross-sectional, multicenter study of patients under 18 years of age with moderate to severe psoriasis who were being treated or had been treated with a systemic drug (conventional or biologic) or phototherapy. We recorded demographic and clinical information, treatments received, tolerance, adverse effects, and response to treatment. RESULTS: Data were collected for 40 patients (60% female; mean age, 13 years) who had received 63 treatments in total. The most common first treatment (n = 40) was phototherapy (administered to 68% of patients), followed by acitretin (15%). The most common treatments overall (n =63) were phototherapy (57%) and methotrexate (16%). At week 12 (evaluation of systemic treatment and phototherapy), 66% of the patients were classified as good responders and 22% as partial responders. The respective rates for week 24 (evaluation of systemic treatment only) were 36% and 32%. The treatments were well tolerated (97%) and adverse effects were reported in just 11% of cases. There were no treatment discontinuations because of adverse effects. CONCLUSIONS: Phototherapy, followed by methotrexate, was the most common treatment for moderate to severe psoriasis in this series of patients under 18 years. The treatments showed a favorable safety profile and were associated with a good response rate of 66% at week 12 (systemic treatment and phototherapy) and 36% at week 24 (systemic treatment only)
Subject(s)
Humans , Male , Female , Adolescent , Psoriasis/drug therapy , Treatment Outcome , Cross-Sectional Studies/methods , Phototherapy , Biological TherapyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Edema/diagnosis , Cellulite/diagnosis , Eosinophilia/diagnosis , Facial Dermatoses/diagnosis , Cheek , Eosinophils/pathology , Eyelids , Prednisone/therapeutic useABSTRACT
Las metástasis cutáneas de cáncer de próstata son extremadamente infrecuentes. Presentamos 2 casos de metástasis cutáneas a distancia de adenocarcinoma de próstata, con localización atípica y destacando 2 tinciones inmunohistoquímicas que pueden ayudar al diagnóstico (fosfatasa ácida prostática y el antígeno prostático específico de membrana prostática), fundamentalmente en aquellos casos en los que el antígeno prostático específico es negativo
Cutaneous metastases of prostate cancer are extremely rare. We present 2 cases of distant cutaneous metastases at atypical locations of prostate adenocarcinoma, and highlight the value of 2 immunohistochemical stains-prostatic acid phosphatase and prostate-specific membrane antigen-that can aid diagnosis, particularly in cases with negative staining for prostate-specific antigen
Subject(s)
Humans , Male , Middle Aged , Aged, 80 and over , Prostatic Neoplasms/complications , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/drug therapy , Prostate-Specific Antigen/analysis , Adenocarcinoma/complications , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Immunohistochemistry/methods , Neoplasm Metastasis/diagnosis , Neoplasm Metastasis/drug therapy , Prostatectomy/methods , Prostatectomy , Prognosis , Skin Neoplasms/complications , Skin Neoplasms/pathologyABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Skin Diseases, Vascular/classification , Skin Diseases, Vascular/etiology , Skin Diseases, Vascular/pathology , Biopsy/instrumentation , Biopsy/methods , Biopsy , Medical History Taking/methods , Laser Therapy/instrumentation , Laser Therapy/methods , Laser Therapy , Lasers, Dye/therapeutic use , Lasers, Dye , Skin Diseases/diagnosisSubject(s)
Cellulitis/diagnosis , Edema/diagnosis , Eosinophilia/diagnosis , Facial Dermatoses/diagnosis , Aged, 80 and over , Cellulitis/drug therapy , Cellulitis/pathology , Cheek , Diagnosis, Differential , Edema/drug therapy , Edema/pathology , Eosinophilia/drug therapy , Eosinophilia/pathology , Eosinophils/pathology , Eyelids , Facial Dermatoses/drug therapy , Facial Dermatoses/pathology , Female , Hand Dermatoses/diagnosis , Hand Dermatoses/drug therapy , Humans , Insect Bites and Stings/diagnosis , Prednisone/therapeutic use , Recurrence , Remission InductionABSTRACT
Cutaneous metastases of prostate cancer are extremely rare. We present 2 cases of distant cutaneous metastases at atypical locations of prostate adenocarcinoma, and highlight the value of 2 immunohistochemical stains-prostatic acid phosphatase and prostate-specific membrane antigen-that can aid diagnosis, particularly in cases with negative staining for prostate-specific antigen.
Subject(s)
Adenocarcinoma/secondary , Prostatic Neoplasms/pathology , Skin Neoplasms/secondary , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Humans , Male , Skin Neoplasms/pathologyABSTRACT
Background. Eosinophilic dermatosis of hematologic disorders is a reactive process that may cause a variety of clinical manifestations. Methods. We report a patient who had outbreaks of skin lesions since the onset of chronic lymphocytic leukaemia. Results. The cutaneous eruptions began as eosinophilic panniculitis and after changed to insect bite-like lesions. Conclusion. We think that eosinophilic panniculitis and insect bite-like lesions may be part of the spectrum of the same entity in patients with hematologic disorders.
ABSTRACT
Interferon is used to treat hepatitis C virus infection and its cutaneous side effects are well known. Recently, interferon-induced sarcoidosis has been reported. We report a new case of sarcoidosis during pegylated interferon alfa and ribavirin treatment with an unusual presentation in a woman with previous episodes of erythema nodusum and nodular vasculitis related to HCV.
Subject(s)
Hypopigmentation/pathology , Adolescent , Adult , Disease Progression , Female , Humans , Young AdultABSTRACT
No disponible
No disponible
